To report the FDA approval of Dupixent (dupilumab) for pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU).
Key Findings:
Dupilumab added to antihistamines reduced itch severity and urticaria activity at 24 weeks.
Higher proportions of patients achieved well-controlled disease or complete response.
Safety profile consistent with previous studies; injection site reactions were the most common adverse events.
Interpretation:
Dupilumab is the first biologic therapy approved in the US for young children with uncontrolled CSU, addressing a significant unmet need in this population.
Limitations:
The studies primarily focused on patients aged 6 years and older, with limited data specifically for the youngest age group.
Conclusion:
Dupilumab expands treatment options for pediatric patients with CSU, demonstrating efficacy and safety in a previously underserved demographic.
